SAGE-547 90 μg/kg/h

DRUG2 trials

Sponsors

Supernus Pharmaceuticals, Inc.

Conditions

Postpartum Depression

Phase 3

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

CompletedNCT02942017

Supernus Pharmaceuticals, Inc.Postpartum Depression

Start: 2016-07-31End: 2017-10-11Updated: 2025-09-15

A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

CompletedNCT02942004

Supernus Pharmaceuticals, Inc.Postpartum Depression

Start: 2016-08-01End: 2017-10-19Updated: 2025-10-14

Related Papers

Brexanolone in Postpartum Depression: <i>Post Hoc</i> Analyses to Help Inform Clinical Decision-Making.

2020-11-1213 citations

Associations between commonly used patient-reported outcome tools in postpartum depression clinical practice and the Hamilton Rating Scale for Depression

Archives of Women s Mental Health2020-07-1410 citations

Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.

2018-08-31393 citations

Phase 3 Study Evaluating Brexanolone, a GABAA Receptor Modulator, in Severe Postpartum Depression [29B]

Obstetrics and Gynecology2018-04-271 citations